MARKET

PRQR

PRQR

ProQR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.26
-0.19
-3.49%
After Hours: 5.26 0 0.00% 16:00 05/22 EDT
OPEN
5.43
PREV CLOSE
5.45
HIGH
5.50
LOW
5.20
VOLUME
75.18K
TURNOVER
--
52 WEEK HIGH
13.28
52 WEEK LOW
4.460
MARKET CAP
262.82M
P/E (TTM)
-3.6243
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PRQR stock price target is 26.91 with a high estimate of 40.30 and a low estimate of 20.15.

EPS

PRQR News

More
ProQR Announces Annual Meeting of Shareholders
Leiden, Netherlands & Cambridge, Mass., May 25, 2020 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation.
GlobeNewswire · 10h ago
ProQR EPS beats by €0.03
ProQR (NASDAQ:PRQR): Q1 GAAP EPS of -€0.32 beats by €0.03. Cash and cash equivalents of €98.1M. Press Release
seekingalpha · 05/07 16:49
ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
Zacks · 05/07 13:55
ProQR Announces First Quarter 2020 Operating and Financial Results
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion.
GlobeNewswire · 05/07 11:00
Does ProQR Therapeutics (NASDAQ:PRQR) Have A Healthy Balance Sheet?
Simply Wall St. · 04/28 13:47
ProQR Therapeutics Filing Shows Registration For $75M Common Stock Offering
Benzinga · 03/31 20:55
AMRN, PSTV, SRG and PBFX among midday movers
Seeking Alpha - Article · 03/31 16:41
ProQr Reports Findings From Three-Month Interim Analysis Of Phase 1/2 Steller Trial Of QR-421a In Adults With Usher Syndrom And nsRP
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse events QR-421a is the second
Benzinga · 03/31 10:02

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About PRQR

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
More

Webull offers kinds of ProQR Therapeutics NV stock information, including NASDAQ:PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions.